How Battling Frizz And Graying Roots Made This Entrepreneur A $600 Million Fortune https://t.co/Yr1d41dfsQ https://t.co/Yr1d41dfsQ ...

RT Token Terminal 📊 (@tokenterminal)🚨 BREAKING: The stablecoin supply on @ethereum surpasses $140 billion.The supply has nearly doubled from January '24 levels. https://t.co/J3D8otykuo ...

Ethereum treasury firm @SharpLinkGaming brought its total ETH holdings to over $1.3 billion at today's prices following purchases last week, the company announced on Tuesday. https://t.co/YPLTYorut8 ...

NASA Confirms A ‘Betel-Buddy’ Is Orbiting Supergiant Star Betelgeuse https://t.co/u6hT2QiLIj ...

The Best Places To Retire Abroad In 2025Nestled along Europe’s North Sea coast, The Netherlands offers an incredible geographic location for European travel and a solid Continental sensibility. https://t.co/1em84xgqlA (Photo: Nicolas Economou/NurPhoto via Getty Images) https://t.co/6LeFBRmeyE ...

The Best Places To Retire Abroad In 2025Nestled along Europe’s North Sea coast, The Netherlands offers an incredible geographic location for European travel and a solid Continental sensibility. https://t.co/lIBQ6kIdPf (Photo: E Plus via Getty Images) https://t.co/2cc86Y87Qz ...

Where Is Cannabis Legal In Europe? https://t.co/iEcxusvYvj https://t.co/iEcxusvYvj ...

DUBLIN, July 22, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2025 second quarter financial results on Tuesday, August 5, 2025, after the close of the U.S. financial markets. Company management will host a live audio webcast at 4:30 p.m. EDT / 9:30 p.m. IST to discuss 2025 second quarter financial results and provide a business and financial update.Interested parties may register for the call in advance here or via the Investors section of the Jazz Pha ...

Core Viewpoint - Rhythm Pharmaceuticals, Inc. is set to report its second quarter 2025 financial results and provide a corporate update on August 5, 2025, highlighting its focus on rare neuroendocrine diseases and the development of its lead asset, setmelanotide [1][4]. Company Overview - Rhythm Pharmaceuticals is a commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with rare neuroendocrine diseases [4]. - The company's lead product, IMCIVREE® (setmelanotide), is an MC4R agonist approved by the FDA for reducing excess body weight and maintaining weight reduction in patients aged 2 years and older with specific genetic obesity conditions [4][5]. - Setmelanotide is also authorized by the European Commission and the UK's MHRA for similar indications in adults and children [4][6]. Upcoming Events - Rhythm Pharmaceuticals will host a live conference call and webcast on August 5, 2025, at 8:00 a.m. ET to discuss its financial results [1]. - Alastair Garfield, Chief Scientific Officer, and David Connolly, Head of Investor Relations, will participate in a fireside chat at the Canaccord Genuity 45th Annual Growth Conference on August 13, 2025, at 12:30 p.m. ET [2]. Product Indications - In the U.S., setmelanotide is indicated for patients with syndromic or monogenic obesity due to Bardet-Biedl syndrome (BBS) or deficiencies in POMC, PCSK1, or LEPR [5]. - In the EU and UK, it is indicated for obesity treatment and hunger control associated with genetically confirmed BBS or loss-of-function biallelic POMC, including PCSK1 and LEPR deficiencies [6]. Clinical Development - Rhythm is advancing a broad clinical development program for setmelanotide in other rare diseases and is also exploring investigational MC4R agonists, bivamelagon and RM-718, along with a preclinical suite of small molecules for congenital hyperinsulinism [4].

BitMine Immersion shares were up slightly in Tuesday trading, a day after Cathie Wood's ARK Invest purchased $182 million of the Ethereum treasury company's stock. https://t.co/0LReh3bv1Y ...